Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2026, Vol. 31 ›› Issue (10): 1392-1399.doi: 10.12092/j.issn.1009-2501.2026.10.010

Previous Articles    

Progress in the use of rituximab in interstitial lung disease

Tianyun YANG(), Zhihong CHEN()   

  1. Department of Respiratory and Critical Care Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
  • Received:2025-11-30 Revised:2026-01-12 Online:2026-10-26 Published:2026-11-11

Abstract:

Interstitial lung disease (ILD) represents a severe pulmonary complication of connective tissue diseases (CTD), and conventional pharmacotherapy yields unsatisfactory therapeutic outcomes. In recent years, the application of therapeutic approaches such as biologics has improved the prognosis of such patients. Rituximab (RTX) is a chimeric human-mouse monoclonal antibody specifically targeting the CD20 antigen on the surface of B lymphocytes. Clinical practice has demonstrated that RTX serves as a valuable therapeutic option for patients with various connective tissue disease-related interstitial lung disease (CTD-ILD) who fail glucocorticoid and immunosuppressive therapy. This article reviews the mechanism of action of RTX and its application in connective tissue disease-associated ILD.

Key words: rituximab, interstitial lung disease, biologic agents, connective tissue diseases

CLC Number: